Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus

Abstract

Objective

This study characterizes an IL-35-mediated regulatory role in patients with systemic lupus erythematosus (SLE).

Methods

Plasma of SLE patients and healthy controls (HCs) was analyzed for the concentrations of IL-35 and soluble gp130 by using ELISA. mRNA expression of IL-35 subunit (p35 and EBI3) and its receptor (gp130 and IL-12Rβ2) in peripheral blood mononuclear cells (PBMCs) was assessed by RT-qPCR. Flow cytometry was performed to evaluate the number of CD4⁺CD25^highCD127⁻Treg cells and the expression of IL-35 receptor on the CD4+ helper (Th) cells and CD19+ B cells. Plasma collected from SLE patients and HCs was assayed for cytokine and chemokine expression by Luminex multiplex assay.

Results

Plasma IL-35 and soluble gp130 levels positively correlated with each other and were significantly higher in patients with severe SLE compared with HCs. Significantly higher levels of inflammatory cytokines/chemokines CCL2, CXCL8, IL-6, interferon (IFN)-γ, IL-10 and IL-17A were observed in plasma of SLE patients than HCs. mRNA levels of IL-35 and its receptor were significantly positively correlated in PBMCs from SLE patients and their levels were higher in SLE than HCs. The increase significantly correlated with changes in SLE Disease Activity Index (SLEDAI) (all p < 0.05). In addition, the number of Treg cells in severe and moderate SLE patients were both significantly lower than HCs, where the ratio of CD4⁺CD25⁻effector T cell %/CD4⁺CD25^highCD127⁻Treg % was found to be significantly higher in severe SLE patients. Furthermore, the expression of gp130 on CD4+ Th cells and percentage of Tregs were positively correlated with each other, and both were negatively correlated with SLEDAI.

Conclusion

Our findings indicate that high level of plasma IL-35 in active SLE patients expressed with low level of IL-35 receptor (gp130) on CD4+ Th cells. These data raise the possibility that the level of IL-35 expression in SLE patients is not sufficient to induce the production of CD4⁺CD25^highCD127⁻Tregs, and subsequently suppress the release of inflammatory cytokines and chemokines upon inflammation.

Keywords

Cytokines interleukin-35 regulatory T cells systemic lupus erythematosus Systemic Lupus Erythematosus Disease Activity Index

Get full access to this article

View all access options for this article.

References

Mok

Lau

. Pathogenesis of systemic lupus erythematosus. J Clin Pathol 2003; 56: 481–490.

Crispín

Oukka

Bayliss

. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008; 181: 8761–8766.

Collison

Vignali

. Interleukin-35: Odd one out or part of the family? Immunol Rev 2008; 226: 248–262.

Collison

Workman

Kuo

. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566–569.

Collison

Delgoffe

Guy

. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol 2012; 13: 290–299.

Collison

Chaturvedi

Henderson

. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11: 1093–1101.

Chaturvedi

Collison

Guy

Workman

Vignali

. Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011; 186: 6661–6666.

Qiu

Song

Yang

. Glucocorticoid downregulates expression of IL-12 family cytokines in systemic lupus erythematosus patients. Lupus 2013; 22: 1011–1016.

Hochberg

. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.

10.

Bombardier

Gladman

Urowitz

Caron

Chang

. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630–640.

11.

Gladman

Urowitz

Goldsmith

. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 809–813.

12.

Luijten

Tekstra

Bijlsma

Bijl

. The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev 2012; 11: 326–329.

13.

Tan

Cohen

Fries

. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–1277.

14.

Schiffenbauer

Simon

. Randomized controlled trials in systemic lupus erythematosus: What has been done and what do we need to do? Lupus 2004; 13: 398–405.

15.

Chan

Wong

. Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus. Arthritis Res Ther 2012; 14: R80–R80.

16.

Moon

Kim

Park

. CD4⁺CD25^highFoxP3⁺ regulatory T-cells in hematologic diseases. Korean J LabMed 2011; 31: 231–237.

17.

Bonelli

von Dalwigk

Savitskaya

Smolen

Scheinecker

. Foxp3 expression in CD4+ T cells of patients with systemic lupus erythematosus: A comparative phenotypic analysis. Ann Rheum Dis 2008; 67: 664–671.

18.

Tsokos

Liossis

. Immune cell signaling defects in lupus: Activation, anergy and death. Immunol 1999; 20: 119–124.

19.

Bonelli

Savitskaya

Steiner

Rath

Smolen

Scheinecker

. Phenotypic and functional analysis of CD4⁺CD25^–Foxp3⁺ T cells in patients with systemic lupus erythematosus. J Immunol 2009; 182: 1689–1695.

20.

Valencia

Yarboro

Illei

Lipsky

. Deficient CD4⁺CD25^high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178: 2579–2588.

21.

Huang

Pirskanen

Ciscombe

Link

Lefvert

. Circulating CD4⁺CD25⁺ and CD4⁺CD25^–T cells in myasthenia gravis. Ann NY Acad Sci 2003; 998: 318–319.

22.

Sun

Qiao

Zhao

Zhu

Xiao

. Increase of circulating CD4⁺CD25⁺ T cells in myasthenia gravis patients with stability and thymectomy. Clin Immunol 2004; 112: 284–289.

23.

Salama

Chaudhry

Holthaus

. Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture’s (anti-GBM) disease. Kidney Int 2003; 64: 1685–1694.

24.

Viglietta

Baecher-Allan

Weiner

Hafler

. Loss of functional suppression by CD4⁺CD25⁺ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004; 199: 971–979.

25.

Ehrenstein

Evans

Singh

. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-alpha therapy. J Exp Med 2004; 200: 277–285.

26.

de Kleer

Wedderburn

Taams

. CD4⁺CD25^bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004; 172: 6435–6443.

27.

Cao

Malmström

Baecher-Allan

Hafler

Klareskog

Trollmo

. Isolation and functional characterization of regulatory CD25^brightCD4⁺ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 2003; 33: 215–223.

28.

Cao

van Vollenhoven

Klareskog

Trollmo

Malmström

. CD25^brightCD4⁺ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004; 6: R335–346.

29.

Vignali

Collison

Workman

. How regulatory T cells work. Nat Rev Immunol 2008; 8: 523–532.

30.

Ouyang

Shi

Liu

. Decreased interleukin 35 and CD4⁺EBI3⁺ T cells in patients with active systemic lupus erythematosus. Am J Med Sci 2014; 348: 156–161.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.33 MB